HIV dominance (Biktarvy moat into 2030s) + lenacapavir PrEP optionality + CAR-T oncology buildout. 79% gross margins reflect the franchise quality. The toll-road customer that keeps spending on manufacturing infrastructure.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$162.98BSnapshot value
Lenacapavir PrEP FDA approval + launch, Biktarvy patent defense, Yescarta CAR-T second-line LBCL expansion, Trodelvy breast cancer readouts, HBV cure pipeline progress
1. Lenacapavir PrEP commercial failure (payer coverage, adoption). 2. Biktarvy patent challenge succeeds earlier than expected. 3. CAR-T growth stalls vs bispecific antibodies. 4. HBV cure trial failure. 5. M&A overpay — dilutive acquisition repeats Immunomedics mistake.
Moderate interest driven by lenacapavir PrEP narrative (HIV prevention轰动). Retail interest above pharma average.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed